» Articles » PMID: 33807773

SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2021 Apr 3
PMID 33807773
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

In late 2019, a global pandemic occurred. The causative agent was identified as a member of the family, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we present an analysis on the substances identified in the human metabolome capable of binding the active site of the SARS-CoV-2 main protease (M). The substances present in the human metabolome have both endogenous and exogenous origins. The aim of this research was to find molecules whose biochemical and toxicological profile was known that could be the starting point for the development of antiviral therapies. Our analysis revealed numerous metabolites-including xenobiotics-that bind this protease, which are essential to the lifecycle of the virus. Among these substances, silybin, a flavolignan compound and the main active component of silymarin, is particularly noteworthy. Silymarin is a standardized extract of milk thistle, , and has been shown to exhibit antioxidant, hepatoprotective, antineoplastic, and antiviral activities. Our results-obtained in silico and in vitro-prove that silybin and silymarin, respectively, are able to inhibit M, representing a possible food-derived natural compound that is useful as a therapeutic strategy against COVID-19.

Citing Articles

A Comprehensive Review on the Antibacterial, Antifungal, Antiviral, and Antiparasitic Potential of Silybin.

Pereira-Filho J, Mendes A, Campos C, Moreira I, Monteiro C, Soczek S Antibiotics (Basel). 2024; 13(11).

PMID: 39596784 PMC: 11591437. DOI: 10.3390/antibiotics13111091.


The Dynamics of OXA-23 β-Lactamase from .

Arrigoni R, Ballini A, Santacroce L, Palese L Int J Mol Sci. 2023; 24(24).

PMID: 38139363 PMC: 10743560. DOI: 10.3390/ijms242417527.


Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors.

Mushebenge A, Ugbaja S, Mbatha N, Khan R, Kumalo H Int J Mol Sci. 2023; 24(21).

PMID: 37958503 PMC: 10647470. DOI: 10.3390/ijms242115518.


Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary Thyroid Cancer.

Xie W, Li H, Lin Q, Ke N Endocr Metab Immune Disord Drug Targets. 2023; 24(6):672-690.

PMID: 37855349 DOI: 10.2174/0118715303248000230922185110.


AI-Aided Search for New HIV-1 Protease Ligands.

Arrigoni R, Santacroce L, Ballini A, Palese L Biomolecules. 2023; 13(5).

PMID: 37238727 PMC: 10216636. DOI: 10.3390/biom13050858.


References
1.
Sanner M . Python: a programming language for software integration and development. J Mol Graph Model. 2000; 17(1):57-61. View

2.
Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

3.
Stoddard S, Stoddard S, Oelkers B, Fitts K, Whalum K, Whalum K . Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site. Viruses. 2020; 12(9). PMC: 7552026. DOI: 10.3390/v12090942. View

4.
Masters P . The molecular biology of coronaviruses. Adv Virus Res. 2006; 66:193-292. PMC: 7112330. DOI: 10.1016/S0065-3527(06)66005-3. View

5.
Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View